{
  "id": "systemic-mastocytosis",
  "title": "Systemic mastocytosis",
  "lang": "en",
  "source_lang": "en",
  "summary": "Systemic mastocytosis is a rare clonal disorder in which abnormal mast cells accumulate in internal organs, causing mediator-related symptoms and, in advanced forms, organ damage.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "Systemic mast cell disease",
    "SM"
  ],
  "generated_at": "2026-11-05",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/systemic-mastocytosis/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/systemic-mastocytosis/",
      "json": "https://aiwiki.page/zh/systemic-mastocytosis.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Systemic mastocytosis is a rare blood-forming tissue disorder characterized by the abnormal accumulation of mast cells in one or more organs outside the skin, most commonly the bone marrow. It is a systemic form of mastocytosis and usually develops in adults. Its effects arise both from substances released by mast cells and, in advanced disease, from tissue infiltration that impairs organ function. The clinical spectrum ranges from indolent disease with a generally favorable outlook to aggressive forms with substantial organ damage."
    },
    {
      "heading": "Biological basis",
      "text": "Mast cells are cells of the immune system that normally reside in tissues and participate in allergic reactions and other immune responses. They contain granules rich in substances such as histamine and tryptase. Release of these and other mediators can produce itching, flushing, abdominal symptoms, low blood pressure, and anaphylaxis.\n\nIn systemic mastocytosis, abnormal mast cells arise from a clone of blood-forming cells. Most adult cases carry an acquired activating mutation in the KIT gene, most commonly KIT D816V. KIT encodes a receptor involved in cell growth and survival; activating mutations allow signaling to persist without its normal regulation.\n\nThe disorder is generally acquired rather than inherited. Nevertheless, inherited factors can influence its manifestations. Hereditary alpha-tryptasemia, a genetic trait associated with increased baseline tryptase, can coexist with systemic mastocytosis and complicate interpretation of laboratory findings.\n\nSystemic mastocytosis is classified as a hematologic neoplasm. This classification does not mean that every case behaves like an aggressive cancer: many patients have stable, nonadvanced disease for years."
    },
    {
      "heading": "Clinical manifestations",
      "text": "Symptoms fall into two overlapping groups.\n\nMast-cell mediator effects can include:\n\n- Episodic flushing, itching, and skin whealing.\n- Abdominal pain, cramping, diarrhea, nausea, and acid-related upper gastrointestinal symptoms.\n- Palpitations, light-headedness, and episodes of low blood pressure.\n- Recurrent anaphylaxis, including reactions associated with insect stings.\n- Fatigue and impaired concentration, which are nonspecific and require consideration of other causes.\n\nTissue and skeletal effects can include:\n\n- Enlargement of the liver, spleen, or lymph nodes.\n- Osteoporosis, vertebral compression fractures, and other skeletal abnormalities.\n- Reduced blood-cell production.\n- In advanced disease, liver dysfunction, portal hypertension, intestinal malabsorption, and weight loss.\n\nMany patients have persistent reddish-brown skin lesions termed maculopapular cutaneous mastocytosis, historically called urticaria pigmentosa. Rubbing a lesion may produce localized swelling and redness, known as Darier’s sign. Skin lesions are not required for systemic disease, and their absence does not exclude a substantial mast-cell burden.\n\nThe severity of mediator-related symptoms does not necessarily correspond to the extent of organ infiltration. Severe anaphylaxis can occur in otherwise indolent disease."
    },
    {
      "heading": "Classification",
      "text": "Classification incorporates mast-cell burden, evidence of organ dysfunction, and the presence of another blood disorder. The World Health Organization and International Consensus Classification use closely related but not identical categories.\n\nMajor clinical categories include:\n\n- Bone marrow mastocytosis: a nonadvanced form without skin lesions and with defined low-burden features. Its placement differs between classification systems.\n- Indolent systemic mastocytosis: systemic disease without mast-cell–related organ damage or an associated hematologic neoplasm.\n- Smoldering systemic mastocytosis: disease with a higher burden or other indicators of increased disease extent, but without the organ damage that defines aggressive disease.\n- Aggressive systemic mastocytosis: mast-cell infiltration causing defined organ damage.\n- Systemic mastocytosis with an associated hematologic neoplasm: systemic mastocytosis occurring alongside another blood-forming tissue neoplasm, often a myeloid disorder. The International Consensus Classification uses a more specifically myeloid-associated category.\n- Mast cell leukemia: a rare form defined by a high proportion of mast cells in bone marrow aspirates; circulating mast cells may or may not be prominent.\n\nAggressive systemic mastocytosis, disease with an associated hematologic neoplasm, and mast cell leukemia are generally grouped as advanced systemic mastocytosis.\n\n“B findings” describe increased disease burden without qualifying organ damage. “C findings” describe organ damage attributable to mast-cell infiltration, such as cytopenias, liver dysfunction, malabsorption with weight loss, or large osteolytic lesions. Osteoporosis alone is not a C finding."
    },
    {
      "heading": "Diagnosis",
      "text": "Diagnosis combines tissue examination, molecular testing, and laboratory findings. A bone marrow biopsy is central in many adult evaluations. Examination assesses mast-cell aggregates, cell shape, abnormal marker expression, and associated blood disorders.\n\nUnder World Health Organization criteria, diagnosis generally requires one major criterion plus at least one minor criterion, or at least three minor criteria.\n\nThe major criterion is multifocal dense aggregates of at least 15 mast cells in bone marrow or another extracutaneous organ.\n\nThe minor criteria concern:\n\n- Atypical or spindle-shaped mast-cell morphology meeting the specified proportion.\n- An activating KIT mutation.\n- Abnormal mast-cell expression of CD25, CD2, or CD30.\n- A persistently elevated baseline serum tryptase concentration above 20 ng/mL, subject to defined qualifications.\n\nTryptase interpretation requires care. An associated myeloid neoplasm can itself elevate tryptase, and hereditary alpha-tryptasemia may require adjustment of the baseline value. A rise during an acute reaction is not equivalent to a persistently elevated baseline. Conversely, a normal or modest baseline tryptase does not exclude systemic mastocytosis.\n\nHighly sensitive molecular methods can detect low levels of KIT D816V in blood or marrow. A negative peripheral-blood result does not independently exclude disease. A complete blood count, biochemical tests, skeletal assessment, and imaging help characterize disease extent and organ function."
    },
    {
      "heading": "Related conditions and diagnostic distinctions",
      "text": "Cutaneous mastocytosis is confined to the skin and is particularly common in children. Childhood skin-limited disease often follows a different course from adult systemic mastocytosis.\n\nMast cell activation syndrome describes recurrent systemic episodes of mast-cell mediator release meeting clinical and biochemical criteria. It is not synonymous with systemic mastocytosis: activation can occur with or without a clonal mast-cell disorder, and the two conditions can coexist.\n\nThe differential diagnosis also includes allergic disease, other causes of anaphylaxis, hereditary alpha-tryptasemia, reactive mast-cell increases, and other hematologic neoplasms. Neither nonspecific symptoms nor an elevated tryptase result alone establishes systemic mastocytosis."
    },
    {
      "heading": "Treatment",
      "text": "Treatment distinguishes control of mediator effects from reduction of the abnormal mast-cell population.\n\nMediator-directed approaches include antihistamines, acid-suppressing medicines, leukotriene-modifying medicines, and mast-cell stabilizing agents. Epinephrine is the first-line emergency treatment for anaphylaxis. Omalizumab, an anti-IgE antibody, has been used in selected patients with recurrent mediator-related reactions; regulatory status and supporting evidence vary by indication.\n\nSkeletal complications receive separate treatment. Symptom severity, fracture risk, and organ involvement can require attention even when the underlying systemic mastocytosis is classified as indolent.\n\nDisease-directed treatment includes targeted therapy against KIT. Midostaurin and avapritinib have established roles in advanced systemic mastocytosis. Avapritinib also has an approved indication for adult indolent systemic mastocytosis in some jurisdictions. Mutation status matters: KIT D816V is generally resistant to imatinib, whereas certain other molecular settings may be sensitive.\n\nOther options in selected advanced cases include cladribine and hematopoietic stem cell transplantation. An associated hematologic neoplasm may require its own treatment. Treatment eligibility and toxicity differ substantially between therapies and disease subtypes."
    },
    {
      "heading": "Course and prognosis",
      "text": "Prognosis depends chiefly on subtype, organ damage, accompanying hematologic disease, blood counts, and molecular features. Indolent systemic mastocytosis generally has a favorable long-term outlook, although mediator symptoms and skeletal disease may substantially affect daily functioning. Progression to advanced disease occurs in a minority.\n\nAdvanced systemic mastocytosis has a less favorable course. Additional mutations, including changes in SRSF2, ASXL1, and RUNX1, contribute prognostic information in relevant patient groups. Outcomes also depend on the associated neoplasm and response to treatment; a single survival estimate does not adequately describe the full disease spectrum."
    }
  ],
  "links": [
    "mast-cell",
    "bone-marrow",
    "mastocytosis",
    "immune-system",
    "histamine",
    "anaphylaxis",
    "mutation",
    "gene",
    "cancer",
    "abdominal-pain",
    "diarrhea",
    "spleen",
    "osteoporosis",
    "diagnosis",
    "biopsy",
    "complete-blood-count",
    "mast-cell-activation-syndrome",
    "differential-diagnosis",
    "antihistamine",
    "epinephrine",
    "targeted-cancer-therapy",
    "hematopoietic-stem-cell-transplantation",
    "prognosis"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}